Science Explorer Back to mapMap
Discussion
Company · Hørsholm · Denmark

MC2 Therapeutics (Denmark)

mc2therapeutics.comROR OpenAlex
Research works
28
▲ 149% vs 2018-21
Citations
131
4.6 per fractional work
Top-10% rate
5.9%
all institutions 10.0%
Open access
67%
world 40%
International
64%
world 18%
MC2 Therapeutics (Denmark)

Not ranked overall: MC2 Therapeutics (Denmark) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does MC2 Therapeutics (Denmark) work in?

In all years, 59% of research at MC2 Therapeutics (Denmark) is in Health Sciences, 35% in Life Sciences. Its largest fields are Medicine (57%), Biochemistry, Genetics and Molecular Biology (14%), Immunology and Microbiology (12%). It does 2.1× the world's share of Health Sciences.

Health Sciences: 17 fractional works · 59.2% of its workMedicine: 16 fractional works · 57.2% of its workRadiology, Nuclear Medicine and Imaging: 2 fractional works · 7.2% of its workHematology: 2 fractional works · 6.5% of its workNeurology: 2 fractional works · 5.6% of its workOncology: 1 fractional works · 5.1% of its workDermatology: 1 fractional works · 4.9% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 4.5% of its workOphthalmology: 1 fractional works · 4.4% of its workGenetics: 1 fractional works · 3.3% of its workPulmonary and Respiratory Medicine: 1 fractional works · 3.3% of its workEpidemiology: 1 fractional works · 2.4% of its workPathology and Forensic Medicine: 1 fractional works · 2.2% of its workRheumatology: 1 fractional works · 2.0% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 1.4% of its workPhysiology: 0 fractional works · 1.4% of its workGastroenterology: 0 fractional works · 0.6% of its workInfectious Diseases: 0 fractional works · 0.6% of its workOtorhinolaryngology: 0 fractional works · 0.5% of its workImmunology and Allergy: 0 fractional works · 0.4% of its workUrology: 0 fractional works · 0.3% of its workSurgery: 0 fractional works · 0.2% of its workPsychiatry and Mental health: 0 fractional works · 0.2% of its workDentistry: 0 fractional works · 1.0% of its workPeriodontics: 0 fractional works · 0.8% of its workOral Surgery: 0 fractional works · 0.2% of its workHealth Professions: 0 fractional works · 0.8% of its workComplementary and Manual Therapy: 0 fractional works · 0.7% of its workSmaller subfields together: 0 fractional works · 0.1% of its workNursing: 0 fractional works · 0.2% of its workLife Sciences: 10 fractional works · 34.9% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 13.6% of its workMolecular Biology: 2 fractional works · 6.3% of its workCancer Research: 1 fractional works · 3.2% of its workGenetics: 1 fractional works · 2.4% of its workBiotechnology: 0 fractional works · 1.6% of its workSmaller subfields together: 0 fractional works · 0.1% of its workImmunology and Microbiology: 3 fractional works · 12.0% of its workImmunology: 3 fractional works · 12.0% of its workPharmacology, Toxicology and Pharmaceutics: 2 fractional works · 6.6% of its workPharmaceutical Science: 2 fractional works · 6.3% of its workPharmacology: 0 fractional works · 0.2% of its workNeuroscience: 1 fractional works · 2.4% of its workNeurology: 1 fractional works · 2.0% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.0% of its workAgricultural and Biological Sciences: 0 fractional works · 0.3% of its workFood Science: 0 fractional works · 0.3% of its workPhysical Sciences: 2 fractional works · 5.3% of its workEngineering: 1 fractional works · 2.6% of its workElectrical and Electronic Engineering: 0 fractional works · 1.4% of its workBiomedical Engineering: 0 fractional works · 1.2% of its workChemistry: 0 fractional works · 1.6% of its workOrganic Chemistry: 0 fractional works · 1.1% of its workSpectroscopy: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.0% of its workComputer Science: 0 fractional works · 0.8% of its workComputational Theory and Mathematics: 0 fractional works · 0.6% of its workArtificial Intelligence: 0 fractional works · 0.2% of its workMaterials Science: 0 fractional works · 0.4% of its workMaterials Chemistry: 0 fractional works · 0.4% of its workSocial Sciences: 0 fractional works · 0.6% of its workSocial Sciences: 0 fractional works · 0.4% of its workEducation: 0 fractional works · 0.4% of its workPsychology: 0 fractional works · 0.2% of its workALL ITS WORKMC2 Therapeutics(Denmark)28fractional works, all years
Life Sciences35%Physical Sciences5%Health Sciences59%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 15 fields, with their numbers
    1. Medicine1657.2%
    2. Dentistry01.0%
    3. Health Professions00.8%
    4. Nursing00.2%
    1. Biochemistry, Genetics and Molecular Biology413.6%
    2. Immunology and Microbiology312.0%
    3. Pharmacology, Toxicology and Pharmaceutics26.6%
    4. Neuroscience12.4%
    5. Agricultural and Biological Sciences00.3%
    1. Engineering12.6%
    2. Chemistry01.6%
    3. Computer Science00.8%
    4. Materials Science00.4%
    1. Social Sciences00.4%
    2. Psychology00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.09× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 3.15× its world share, 3 worksBiochemistry, Geneti…Immunology and Microbiology: 16.85× its world share, 3 worksImmunology and Micro…Neuroscience: 2.01× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 21.16× its world share, 1 worksPharmacology, Toxico…Chemistry: 1.11× its world share, 0 worksChemistryComputer Science: 0.16× its world share, 0 worksComputer ScienceEngineering: 0.20× its world share, 1 worksEngineeringMaterials Science: 0.17× its world share, 0 worksMaterials ScienceDentistry: 2.40× its world share, 0 worksDentistryHealth Professions: 0.45× its world share, 0 worksHealth ProfessionsMedicine: 2.37× its world share, 8 worksMedicineNursing: 0.52× its world share, 0 worksNursingPsychology: 0.11× its world share, 0 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 21.2×. Every wedge is a field page.

All 14 fields, with their numbers
  1. Pharmacology, Toxicology and Pharmaceutics21.16×1 works
  2. Immunology and Microbiology16.85×3 works
  3. Biochemistry, Genetics and Molecular Biology3.15×3 works
  4. Dentistry2.40×0 works
  5. Medicine2.37×8 works
  6. Neuroscience2.01×1 works
  7. Chemistry1.11×0 works
  8. Nursing0.52×0 works
  9. Health Professions0.45×0 works
  10. Engineering0.20×1 works
  11. Materials Science0.17×0 works
  12. Computer Science0.16×0 works
  13. Psychology0.11×0 works
  14. Agricultural and Biological Sciences0.09×0 works

Who are the top researchers at MC2 Therapeutics (Denmark)?

Ranked on the quality score, Morten Præstegaard lead among researchers whose main affiliation is MC2 Therapeutics (Denmark).

  1. 1 Morten Præstegaard Denmark · #4,812,077 worldwide 207 citations · 32 works
All ranked researchers at MC2 Therapeutics (Denmark)

What are the most cited papers from MC2 Therapeutics (Denmark)?

The most cited paper from MC2 Therapeutics (Denmark) is "Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis" (Jorge Peiró Cadahía, Jon Bondebjerg, Christian A. Hansen et al., 2018), with 73 citations. Next come "Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin–restricted miRNA antagonists of miR-27" (71) and "A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis" (45).

Most cited papers
#PaperReleasedCitations
1 Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis Jorge Peiró Cadahía, Jon Bondebjerg, Christian A. Hansen et al. · Journal of Medicinal Chemistry Open access 31 Mar 2018 73
2 Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin–restricted miRNA antagonists of miR-27 Jennifer A. Young et al. · Blood 6 Sep 2013 71
3 A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis Andreas Pinter, L. J. Green, Johan Selmer et al. · Journal of the European Academy of Dermatology and Venereology Open access 10 Oct 2021 45
4 Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events Jaume Mora, Gcf Chan, Daniel A. Morgenstern et al. · Cancer Reports Open access 17 May 2022 29
5 Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application Morten Præstegaard, D. Fraser Steele, Nigel Crutchley · Dermatology and Therapy Open access Sep 2022 28
All 72 most cited papers, with filters and sorting

Which keywords describe research at MC2 Therapeutics (Denmark)?

By fractional works in all years, weighted toward what it does more of than the world: Immunotherapy, Inflammatory Cytokines, Inflammation, Staging System, Regulatory T Cells, Targeted Therapy, Immune System and IL-17.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 30 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 30 words, with their numbers
  1. Immunotherapy3▲ 18×12 topics
  2. Inflammation3▲ 4.8×16 topics
  3. Inflammatory Cytokines3▲ 134×2 topics
  4. Epidemiology3▲ 2.3×12 topics
  5. Staging System2▲ 114×2 topics
  6. Regulatory T Cells2▲ 57×2 topics
  7. Targeted Therapy2▲ 29×5 topics
  8. Immune System2▲ 18×2 topics
  9. IL-172▲ 228×1 topic
  10. TH17 Cells2▲ 228×1 topic
  11. Genetic Mutations2▲ 10×5 topics
  12. Thrombosis2▲ 24×4 topics
  13. Prognosis1▲ 15×3 topics
  14. Therapy1▲ 23×2 topics
  15. Neurodegeneration1▲ 15×4 topics
  16. ALK1▲ 130×1 topic
  17. Chemotherapy1▲ 6.0×6 topics
  18. Neuroblastoma1▲ 130×1 topic
  19. PET Imaging1▲ 20×4 topics
  20. Clinical Trials1▲ 6.5×4 topics
  21. Dry Eye Disease1▲ 108×1 topic
  22. Immune Response1▲ 6.3×5 topics
  23. Microneedles1▲ 167×1 topic
  24. Nanoparticles1▲ 2.9×2 topics
  25. Ocular Surface1▲ 108×1 topic
  26. Solid Lipid Nanoparticles1▲ 167×1 topic
  27. Treatment1▲ 2.9×6 topics
  28. Filaggrin1▲ 87×1 topic
  29. Immune Dysregulation1▲ 45×2 topics
  30. Skin Microbiome1▲ 87×1 topic

Which research topics does MC2 Therapeutics (Denmark) publish most on?

By volume in 2022-now: Psoriasis: Treatment and Pathogenesis, Advancements in Transdermal Drug Delivery, Platelet Disorders and Treatments and Dermatology and Skin Diseases.

Psoriasis: Treatment and…2Psoriasis: Treatment and Pathogenesis: 2 fractional worksAdvancements in Transdermal Drug Delivery: 1 fractional worksPlatelet Disorders and T…1Platelet Disorders and Treatments: 1 fractional worksDermatology and Skin Dis…1Dermatology and Skin Diseases: 1 fractional worksNeuroblastoma Research and Treatments: 1 fractional worksMultiple Myeloma Research and Treatments: 0 fractional worksCoagulation, Bradykinin,…0Coagulation, Bradykinin, Polyphosphates, and Angioedema: 0 fractional worksPharmaceutical studies and practices: 0 fractional worksRadiopharmaceutical Chemistry and Applications: 0 fractional worksNeuroinflammation and Neurodegeneration Mechanisms: 0 fractional works
ImmunologyPharmaceutical ScienceHematologyDermatology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Psoriasis: Treatment and Pathogenesis Immunology 2 works
  2. 2 Advancements in Transdermal Drug Delivery Pharmaceutical Science 1 works
  3. 3 Platelet Disorders and Treatments Hematology 1 works
  4. 4 Dermatology and Skin Diseases Dermatology 1 works
  5. 5 Neuroblastoma Research and Treatments Neurology 1 works
  6. 6 Multiple Myeloma Research and Treatments Hematology 0 works
  7. 7 Coagulation, Bradykinin, Polyphosphates, and Angioedema Genetics 0 works
  8. 8 Pharmaceutical studies and practices Pediatrics, Perinatology and Child Health 0 works
  9. 9 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
  10. 10 Neuroinflammation and Neurodegeneration Mechanisms Neurology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available66.8%not open33.2%

World: 40% of research is openly available.

with international co-authors63.6%domestic only36.4%

World: 18% is written across borders.

How has MC2 Therapeutics (Denmark)'s research output changed?

Output in 2022-2025 was 149% higher than in 2018-2021.

still counting201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is MC2 Therapeutics (Denmark) as a percentage of every work published that year, 0.000028% in 2024.

still counting0.000050%0.00010%0.00015%MC2 Therapeutics (Denmark)0.000082% in 20252020

Fractional works of MC2 Therapeutics (Denmark) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Hørsholm

All research institutions in Hørsholm

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about MC2 Therapeutics (Denmark). Posts are plain text and can be reported.